In light of the emergence of the novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and the urgent need to mitigate the pathogen’s spread, the National Cancer Institute (NCI) and the National Institute of Allergy and Infectious Disease (NIAID) are establishing a Serological Sciences Network of Excellence to mobilize collaborative efforts to develop serological assays of high specificity and high sensitivity for deployment to test for SARS-CoV-2 induced immune responses and to rapidly expand national serological testing capacity.
Leidos Biomedical Research, Inc.
Proposal Due Date:
Thursday, July 16, 2020
Research & Development Services & Subcontracts
NCI OA Contract Number:
75N91019D00024 – NCI-FFRDC
Please contact Heather Sewell at NCIFSSN@nih.gov to request a copy of the Solicitation Package